Navigation Links
Curemark Attends North American Bio Forum at Canadian Government Invitation
Date:9/13/2010

RYE, N.Y., Sept. 13 /PRNewswire/ -- Matthew F. Heil, Ph.D., senior vice president of research and development at Curemark LLC (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, recently attended the North American Bio Forum 2010 in Laval, Canada, at the invitation of the Canadian government/Laval Technopole, Curemark said.  

Held by the Laval Technopole International Business Centre and The Biotech City on September 1 and 2, the Forum discussed "From Discovery to Clinical Trials – Securing a Third Party Alliance." The conference was attended by international pharmaceutical and biotech executives and researchers from North America and around the world.

"It was extremely gratifying to be invited to join this conference organized and hosted in Laval, one of Canada's premier centers for biotech research and innovation," Heil said.  "With the dedicated commitment of the public sector, this area has become a thriving science hub attracting scores of pharmaceutical and biotech companies, research facilities and start-ups."

Curemark is currently developing an autism treatment, CM-AT, which is now in Phase III clinical trials.  CM-AT targets enzyme deficiencies in autistic children that affect the availability of amino acids, the building blocks of chemicals essential to brain function.  Curemark's autism therapy has been granted Fast Track status by the U.S. Food and Drug Administration (FDA).  

The FDA also has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial to study the use of the company's compound CM-4612 in the treatment of attention deficit hyperactivity disorder (ADHD).

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Curemark Presents at Springboard Enterprises Life Sciences Forum
2. US Oncology Clinical Development Attends Partnerships With CROs
3. Northwestern chemists take gold, mass-produce Beijing Olympic logo
4. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
5. Natures Premium(R) Brand First Fresh Pork in North America to Carry DNA TraceBack(R) Seal of Authenticity
6. North Dakota Pharmacists and Medication Management Systems Partner to Deliver Quality MTM Services to Patients With Diabetes
7. ESA Receives 2008 Frost & Sullivan North American Technology Innovation Award for Development of Integrated Metabolomics Systems
8. Northwest Secures US$1.0 Million Debt Financing
9. Endovascular Forum Inc.s President to Participate in Health 2.0 Northeast Panel
10. Circassia Acquires North American and Japanese Rights to Dopexamine
11. Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
(Date:10/10/2017)... ... October 10, 2017 , ... The ... prestigious awards honoring scientists who have made outstanding contributions to analytical ... during Pittcon 2018, the world’s leading conference and exposition for laboratory science, which ...
Breaking Biology Technology:
(Date:10/4/2017)... Oct. 4, 2017  GCE Solutions, a global clinical research organization ... document anonymization solution on October 4, 2017. Shadow is designed to ... comply with policy 0070 of the European Medicines Agency (EMA) in ... ... ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
Breaking Biology News(10 mins):